Aradigm Stock Price, News & Analysis (NASDAQ:ARDM)

$4.68 0.35 (8.08 %)
(As of 12/12/2017 12:55 PM ET)
Previous Close$4.33
Today's Range$4.21 - $4.75
52-Week Range$0.78 - $5.68
Volume158,000 shs
Average Volume159,309 shs
Market Capitalization$65.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58

About Aradigm (NASDAQ:ARDM)

Aradigm logoAradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Receive ARDM News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDM
CUSIPN/A
Phone510-265-9000

Debt

Debt-to-Equity Ratio-1.59%
Current Ratio1.65%
Quick Ratio1.65%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$190,000.00
Price / Sales373.17
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book66.86

Profitability

Trailing EPS($0.98)
Net Income$-32,930,000.00
Net Margins-118.37%
Return on Equity-665.03%
Return on Assets-80.24%

Miscellaneous

Employees23
Outstanding Shares15,150,000

Aradigm (NASDAQ:ARDM) Frequently Asked Questions

What is Aradigm's stock symbol?

Aradigm trades on the NASDAQ under the ticker symbol "ARDM."

How were Aradigm's earnings last quarter?

Aradigm Corporation (NASDAQ:ARDM) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.05. The firm had revenue of $2.73 million for the quarter. Aradigm had a negative net margin of 118.37% and a negative return on equity of 665.03%. View Aradigm's Earnings History.

When will Aradigm make its next earnings announcement?

Aradigm is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for Aradigm.

Where is Aradigm's stock going? Where will Aradigm's stock price be in 2017?

1 brokers have issued 1-year price objectives for Aradigm's stock. Their predictions range from $10.00 to $10.00. On average, they expect Aradigm's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Aradigm.

Who are some of Aradigm's key competitors?

Who are Aradigm's key executives?

Aradigm's management team includes the folowing people:

  • Virgil D. Thompson, Independent Chairman of the Board (Age 78)
  • Igor Gonda Ph.D., President, Chief Executive Officer, Director (Age 68)
  • Nancy E. Pecota, Chief Financial Officer, Vice President - Finance (Age 54)
  • Juergen Froehlich, Chief Medical Officer (Age 58)
  • David Bell, Director (Age 61)
  • Frederick M. Hudson CPA, Independent Director (Age 71)
  • John M. Siebert Ph.D., Independent Director (Age 77)

Who owns Aradigm stock?

Aradigm's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Jane Street Group LLC (0.19%). View Institutional Ownership Trends for Aradigm.

Who bought Aradigm stock? Who is buying Aradigm stock?

Aradigm's stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for Aradigm.

How do I buy Aradigm stock?

Shares of Aradigm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aradigm's stock price today?

One share of Aradigm stock can currently be purchased for approximately $4.68.

How big of a company is Aradigm?

Aradigm has a market capitalization of $65.61 million and generates $190,000.00 in revenue each year. The company earns $-32,930,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Aradigm employs 23 workers across the globe.

How can I contact Aradigm?

Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]


MarketBeat Community Rating for Aradigm (ARDM)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aradigm (NASDAQ:ARDM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00N/AN/A
Price Target Upside: 295.26% upside295.26% upsideN/AN/A

Aradigm (NASDAQ:ARDM) Consensus Price Target History

Price Target History for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ:ARDM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$7.50 -> $10.00MediumView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Aradigm (NASDAQ:ARDM) Earnings History and Estimates Chart

Earnings by Quarter for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ ARDM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2018        
11/2/2017Q3 2017($0.31)($0.26)$2.73 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.30)$0.07$7.68 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.43)($0.25)$1.69 millionViewN/AView Earnings Details
3/28/2017Q4 2016($0.37)($0.54)$0.13 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.53)($0.55)$0.05 millionViewN/AView Earnings Details
8/10/2016Q2($0.59)($0.59)$0.01 millionViewN/AView Earnings Details
5/10/2016Q1($0.59)($0.55)$0.01 millionViewN/AView Earnings Details
3/15/2016Q415($0.55)($0.63)$0.04 millionViewN/AView Earnings Details
11/11/2015Q3($0.19)($0.38)$4.67 millionViewN/AView Earnings Details
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details
5/11/2015Q1($0.06)($0.08)$8.77 millionViewN/AView Earnings Details
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Aradigm (NASDAQ:ARDM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.74 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS

Dividends

Dividend History for Aradigm (NASDAQ:ARDM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aradigm (NASDAQ ARDM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 32.08%
Insider Trades by Quarter for Aradigm (NASDAQ:ARDM)
Institutional Ownership by Quarter for Aradigm (NASDAQ:ARDM)

Aradigm (NASDAQ ARDM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/4/2017Juergen Kurt FroehlichInsiderSell3,765$1.51$5,685.15View SEC Filing  
10/4/2016Juergen Kurt FroehlichInsiderSell423$6.76$2,859.48View SEC Filing  
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aradigm (NASDAQ ARDM) News Headlines

Source:
DateHeadline
Aradigm Announces FDA Advisory Committee Meeting for LinhaliqAradigm Announces FDA Advisory Committee Meeting for Linhaliq
finance.yahoo.com - December 1 at 4:30 PM
ETFs with exposure to Aradigm Corp. : December 1, 2017ETFs with exposure to Aradigm Corp. : December 1, 2017
finance.yahoo.com - December 1 at 4:30 PM
ETFs with exposure to Aradigm Corp. : November 20, 2017ETFs with exposure to Aradigm Corp. : November 20, 2017
finance.yahoo.com - November 20 at 3:17 PM
ETFs with exposure to Aradigm Corp. : November 8, 2017ETFs with exposure to Aradigm Corp. : November 8, 2017
finance.yahoo.com - November 8 at 6:14 PM
Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York CityAradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City
finance.yahoo.com - November 7 at 5:46 PM
Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 5:46 PM
Aradigm Corporation (ARDM) Announces  Earnings ResultsAradigm Corporation (ARDM) Announces Earnings Results
www.americanbankingnews.com - November 3 at 11:38 PM
Aradigm Announces Third Quarter 2017 Financial ResultsAradigm Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:31 PM
Aradigm Announces Third Quarter 2017 Financial ResultsAradigm Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:31 PM
Aradigm reports 3Q lossAradigm reports 3Q loss
finance.yahoo.com - November 2 at 4:31 PM
Aradigm reports 3Q lossAradigm reports 3Q loss
finance.yahoo.com - November 2 at 4:31 PM
Aradigm Corporation (ARDM) Scheduled to Post Quarterly Earnings on TuesdayAradigm Corporation (ARDM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
Aradigm Corporation (ARDM) vs. Flexion Therapeutics (FLXN) Head to Head ReviewAradigm Corporation (ARDM) vs. Flexion Therapeutics (FLXN) Head to Head Review
www.americanbankingnews.com - October 26 at 7:58 AM
Head-To-Head Review: Dynavax Technologies Corporation (DVAX) and Aradigm Corporation (ARDM)Head-To-Head Review: Dynavax Technologies Corporation (DVAX) and Aradigm Corporation (ARDM)
www.americanbankingnews.com - October 25 at 8:37 AM
Zacks Investment Research Downgrades Aradigm Corporation (ARDM) to HoldZacks Investment Research Downgrades Aradigm Corporation (ARDM) to Hold
www.americanbankingnews.com - October 17 at 5:50 PM
Reviewing Paratek Pharmaceuticals (PRTK) and Aradigm Corporation (ARDM)Reviewing Paratek Pharmaceuticals (PRTK) and Aradigm Corporation (ARDM)
www.americanbankingnews.com - October 13 at 8:26 AM
Aradigm Regains Compliance with NASDAQ Listing RequirementsAradigm Regains Compliance with NASDAQ Listing Requirements
finance.yahoo.com - October 10 at 5:21 PM
New Research Coverage Highlights Aradigm, Social Reality Inc, Rentech, PayPal, JPMorgan Chase, and Helios and Matheson Analytics ­Consolidated Revenues, Company Growth, and ExpectationsNew Research Coverage Highlights Aradigm, Social Reality Inc, Rentech, PayPal, JPMorgan Chase, and Helios and Matheson Analytics ­Consolidated Revenues, Company Growth, and Expectations
finance.yahoo.com - October 10 at 5:21 PM
Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns?Can Aradigm Corporation (ARDM) Improve Your Portfolio Returns?
finance.yahoo.com - October 9 at 4:58 PM
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review StatusAradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
finance.yahoo.com - October 2 at 3:54 PM
Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for LinhaliqCorporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq
finance.yahoo.com - October 2 at 3:54 PM
Aradigm, NDA for Linhaliq Accepted by FDA With Priority Review, Catalyst and Pipeline ReviewAradigm, NDA for Linhaliq Accepted by FDA With Priority Review, Catalyst and Pipeline Review
finance.yahoo.com - October 2 at 3:54 PM
Contrasting Aradigm Corporation (ARDM) & Its CompetitorsContrasting Aradigm Corporation (ARDM) & Its Competitors
www.americanbankingnews.com - September 28 at 6:22 AM
U.S. Futures Cautiously Lower Ahead of Speakers, DataU.S. Futures Cautiously Lower Ahead of Speakers, Data
www.nasdaq.com - September 27 at 7:56 PM
Pro-Trader Daily: Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for LinhaliqPro-Trader Daily: Corporate News Blog - Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq
www.finanznachrichten.de - September 27 at 7:56 PM
Aradigm Corp. (ARDM) Announces FDA Accepts Linhaliq NDA with Priority Review StatusAradigm Corp. (ARDM) Announces FDA Accepts Linhaliq NDA with Priority Review Status
www.streetinsider.com - September 27 at 7:56 PM
Aradigm Corporation (ARDM) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowAradigm Corporation (ARDM) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 7:56 PM
Aradigm Corporation (ARDM) Receives "Buy" Rating from Ladenburg Thalmann Financial ServicesAradigm Corporation (ARDM) Receives "Buy" Rating from Ladenburg Thalmann Financial Services
www.americanbankingnews.com - September 25 at 6:00 PM
20 Biggest Mid-Day Gainers For Monday20 Biggest Mid-Day Gainers For Monday
feeds.benzinga.com - September 25 at 1:40 PM
Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
finance.yahoo.com - September 22 at 1:25 PM
Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis PatientsAradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
finance.yahoo.com - September 15 at 4:22 PM
Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual CongressAradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
finance.yahoo.com - September 5 at 5:40 PM
Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ...Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ...
www.nasdaq.com - August 15 at 4:59 PM
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with LinhaliqAradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq
finance.yahoo.com - August 15 at 4:59 PM
Aradigm Corporation (NASDAQ:ARDM) Releases Quarterly  Earnings Results, Beats Estimates By $0.37 EPSAradigm Corporation (NASDAQ:ARDM) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS
www.americanbankingnews.com - August 11 at 2:42 PM
Aradigm Announces Second Quarter 2017 Financial ResultsAradigm Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:26 PM
Aradigm posts 2Q profitAradigm posts 2Q profit
finance.yahoo.com - August 10 at 5:26 PM
Aradigm Corporation (NASDAQ:ARDM) to Release Earnings on TuesdayAradigm Corporation (NASDAQ:ARDM) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
Aradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis BronchiectasisAradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
www.streetinsider.com - July 29 at 8:45 PM
Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis BronchiectasisAradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
finance.yahoo.com - July 27 at 4:05 PM
BRIEF-Aradigm Corp presents analysis of results for phase 3 orbit-3, orbit-4 clinical trialsBRIEF-Aradigm Corp presents analysis of results for phase 3 orbit-3, orbit-4 clinical trials
www.businessinsider.com - July 8 at 3:41 PM
Quietly, Spanish company makes fifth Bay Area biotech investment in 4 yearsQuietly, Spanish company makes fifth Bay Area biotech investment in 4 years
www.bizjournals.com - July 8 at 6:22 AM
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 9:04 PM
Aradigm Announces Fourth Quarter 2016 and Full Year Financial ResultsAradigm Announces Fourth Quarter 2016 and Full Year Financial Results
us.rd.yahoo.com - March 28 at 3:37 PM
ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - December 6 at 12:40 PM
Aradigms Inhaled Antibiotic Fails Study (ARDM)Aradigm's Inhaled Antibiotic Fails Study (ARDM)
www.investopedia.com - December 3 at 8:44 AM
Aradigm Lung Infection Antibiotic Fails Trial (ARDM)Aradigm Lung Infection Antibiotic Fails Trial (ARDM)
www.investopedia.com - December 2 at 9:01 PM
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ...Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ...
www.businesswire.com - December 1 at 3:41 PM
Mid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak OutlookMid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak Outlook
www.nasdaq.com - December 1 at 3:41 PM
7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted)7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted)
us.rd.yahoo.com - December 1 at 3:41 PM

SEC Filings

Aradigm (NASDAQ:ARDM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aradigm (NASDAQ:ARDM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aradigm (NASDAQ ARDM) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.